Tosedostat and OPAXIO study results to be presented at ASCO Annual Meeting

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced that data from a study with OPAXIO™ (paclitaxel poliglumex or PPX), in patients with newly diagnosed high-grade gliomas, and interim results from a study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia ("AML"), will be presented at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 3-7, 2011, in Chicago, Illinois. Both studies were selected for oral poster discussion sessions.

Suriya A. Jeyapalan, M.D., M.P.H., Assistant Professor of Neurology and Neuro-Surgery at Brown University Oncology Group, an investigator on the OPAXIO study, is scheduled to present the data on Friday, June 3, 2011 during the Central Nervous System Tumors session that will be held from 2:00 to 6:00 p.m., and the poster will be part of a oral discussion session from 5:00 to 6:00 p.m. Central Time. The presentation, abstract #2036, is titled, "A phase II study of paclitaxel poliglumex (PPX), temozolamide (TMZ), and radiation (RT) for newly diagnosed high-grade gliomas."

Jorge Cortes, M.D., of The University of Texas MD Anderson Cancer Center, an investigator on the tosedostat study, is scheduled to present the data on Friday, June 3, 2011, during the Leukemia, Myelodysplasia, and Transplantation session that will be held from 2:00 to 6:00 p.m., and the poster will also be included in a discussion session from 5:00 to 6:00 p.m. Central Time. The presentation, abstract #6517, is titled, "Interim results of OPAL, a study of tosedostat in elderly relapsed/refractory AML."

SOURCE Cell Therapeutics, Inc.